Integra LifeSciences Holdings Co. (NASDAQ:IART) Shares Sold by Wellington Management Group LLP

Wellington Management Group LLP lowered its position in Integra LifeSciences Holdings Co. (NASDAQ:IART) by 77.1% during the 4th quarter, Holdings Channel.com reports. The firm owned 2,506,138 shares of the life sciences company’s stock after selling 8,417,221 shares during the quarter. Wellington Management Group LLP’s holdings in Integra LifeSciences were worth $56,839,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently made changes to their positions in IART. Principal Financial Group Inc. increased its position in Integra LifeSciences by 18.7% in the 3rd quarter. Principal Financial Group Inc. now owns 401,432 shares of the life sciences company’s stock valued at $7,294,000 after acquiring an additional 63,266 shares during the period. BNP Paribas Financial Markets increased its holdings in shares of Integra LifeSciences by 824.5% during the third quarter. BNP Paribas Financial Markets now owns 111,775 shares of the life sciences company’s stock valued at $2,031,000 after purchasing an additional 99,685 shares during the period. Charles Schwab Investment Management Inc. raised its stake in shares of Integra LifeSciences by 15.3% during the third quarter. Charles Schwab Investment Management Inc. now owns 944,282 shares of the life sciences company’s stock valued at $17,158,000 after purchasing an additional 125,620 shares in the last quarter. MetLife Investment Management LLC lifted its holdings in Integra LifeSciences by 129.1% in the third quarter. MetLife Investment Management LLC now owns 39,638 shares of the life sciences company’s stock worth $720,000 after purchasing an additional 22,334 shares during the period. Finally, Nisa Investment Advisors LLC grew its position in Integra LifeSciences by 599.6% in the 4th quarter. Nisa Investment Advisors LLC now owns 3,267 shares of the life sciences company’s stock valued at $74,000 after buying an additional 2,800 shares in the last quarter. Institutional investors own 84.78% of the company’s stock.

Integra LifeSciences Stock Performance

NASDAQ:IART opened at $19.57 on Friday. The company has a 50-day moving average of $23.37 and a 200-day moving average of $22.30. The firm has a market cap of $1.51 billion, a price-to-earnings ratio of -217.42, a price-to-earnings-growth ratio of 0.73 and a beta of 1.24. The company has a current ratio of 1.20, a quick ratio of 0.73 and a debt-to-equity ratio of 0.79. Integra LifeSciences Holdings Co. has a twelve month low of $16.81 and a twelve month high of $34.79.

Integra LifeSciences (NASDAQ:IART) last issued its earnings results on Tuesday, February 25th. The life sciences company reported $0.97 earnings per share for the quarter, topping analysts’ consensus estimates of $0.85 by $0.12. Integra LifeSciences had a negative net margin of 0.42% and a positive return on equity of 12.35%. The firm had revenue of $442.65 million during the quarter, compared to analysts’ expectations of $445.15 million. During the same period last year, the firm posted $0.89 earnings per share. The firm’s revenue for the quarter was up 11.5% compared to the same quarter last year. Analysts forecast that Integra LifeSciences Holdings Co. will post 2.45 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Separately, Argus raised shares of Integra LifeSciences from a “hold” rating to a “buy” rating in a research note on Monday, March 31st. Three investment analysts have rated the stock with a sell rating, five have assigned a hold rating and two have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Integra LifeSciences currently has an average rating of “Hold” and an average price target of $23.00.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.